• KOL
    • Lisdexamfetamine Dimesylate
    • John Giblin
    • John Giblin: Influence Statistics

      John Giblin

      John Giblin

      From the *Menninger Department of Psychiatry, Baylor College of Medicine,Houston; †Westex Clinical Investigations, Lubbock, TX; ‡US Medical, Novartis Pharmaceuticals ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      John Giblin:Expert Impact

      Concepts for whichJohn Giblinhas direct influence:Lisdexamfetamine dimesylate,Oros methylphenidate,Ldx adults,Lisdexamfetamine dimesylate ldx,Crossover study,Lisdexamfetamine dimesylate adults,Adults adhd,Hyperactivity disorder.

      John Giblin:KOL impact

      Concepts related to the work of other authors for whichfor which John Giblin has influence:Lisdexamfetamine dimesylate,Hyperactivity disorder,Adults adhd,Attention deficit,Children adolescents,School performance,College students.

      KOL Resume for John Giblin

      Year
      2012

      From the *Menninger Department of Psychiatry, Baylor College of Medicine,Houston; †Westex Clinical Investigations, Lubbock, TX; ‡US Medical, Novartis Pharmaceuticals Corporation, East Hanover, NJ; §Pediatric Trials Division, Clinical Study Centers, LLC, Little Rock, AR; ∥Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, NV; ¶Biostatistics, US Medical; and #Clinical Development and Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ.

      2011

      Clinical Study Centers, LLC, Little Rock, AK, USA

      2010

      Clinical Study Centers, LLC, Little Rock, AR, USA

      Sample of concepts for which John Giblin is among the top experts in the world.
      Concept World rank
      postdose sessions #5
      week ldx #5
      attemptedcorrect #6
      ldx permp scores #6
      crossover phase adults #6
      permp scores placebo #6
      phase lisdexamfetamine #7
      assess lisdexamfetamine #7
      aima improvement #7
      5 ldx #7
      doseoptimization phase #7
      doseoptimization phase quality #7
      participants doseoptimization phase #7
      4 lisdexamfetamine #7
      dimesylate adult #7
      life improvements adults #7
      hours permp #8
      permp assessments remission #8
      safety assessments teaes #8
      postdose sizes #8
      openlabel doseoptimization #8
      20 child cross #8
      20 dexmethylphenidate #8
      fourth editiondiagnosed adhd #8
      adult prompts remission #8
      adults awe #8
      crossover week ldx #8
      ldx teaes #8
      017 remission #8
      permp assessments #8
      sizes 14 hours #8
      016 permp #8
      adhd impact module #8
      prompts remission #8
      ldx 4 #8
      awe ldx #8
      permpa #8
      avg 1012 #8
      sizes permpa #8
      ldx awe #8
      size awe #8
      assessed permp #8
      permpcorrect scores #8
      20 dmpher #8
      permp 08 #8
      lisdexamfetamine dimesylate awe #8
      awe medium #8
      corrected skamp #8
      017 permp #8
      dmpher 20 #9

      Prominent publications by John Giblin

      KOL-Index: 16541

      BACKGROUND: Duration of efficacy and safety of lisdexamfetamine dimesylate (LDX) was assessed in adults (18-55 years) with attention-deficit/hyperactivity disorder (ADHD) using the simulated adult workplace environment.

      METHODS: After open-label dose optimization (4-week) with LDX, 30-70 mg/d, subjects entered a 2-week randomized, double-blind, placebo-controlled crossover phase. Efficacy assessments included the Permanent Product Measure of Performance (PERMP) total score ...

      Known for Lisdexamfetamine Dimesylate | Ldx Adults | Hyperactivity Disorder | Crossover Study | Workplace Environment
      KOL-Index: 10241

      Background: Long-acting methylphenidate formulations provide control of attention-deficit hyperactivity disorder (ADHD) symptoms for up to 12 hours; however, not all formulations have rapid onset of therapeutic effect, which is essential for providing symptom control during morning hours. The primary objective of this randomized, double-blind, crossover study was to assess the efficacy of dexmethylphenidate extended release (ER) versus placebo by measuring the change from pre-dose to 0.5 ...

      Known for Hyperactivity Disorder | Crossover Study | Daily Dexmethylphenidate | Post Dose | Laboratory Classroom
      KOL-Index: 9425

      OBJECTIVE: To examine duration of efficacy of lisdexamfetamine dimesylate (LDX) in adults with attention-deficit/hyperactivity disorder (ADHD) by effect size in performance and symptom improvement in a simulated adult workplace environment (AWE).

      METHODS: Adults (aged 18-55 years) with ADHD enrolled in the AWE study of LDX with open-label dose-optimization and randomized, placebo-controlled, double-blind, 2-way crossover phases. Efficacy measures included the Permanent Product Measure of ...

      Known for Lisdexamfetamine Dimesylate | Hyperactivity Disorder | Adults Adhd | Adult Attention | Efficacy Measures
      KOL-Index: 8635

      OBJECTIVE: To assess improvements in quality of life measurements during the open-label portion of a trial examining duration of efficacy of lisdexamfetamine dimesylate in a simulated adult workplace environment.

      METHODS: A 4-week, open-label, dose-optimization phase followed by a randomized, double-blind, multicenter, placebo-controlled, 2-way crossover phase to evaluate safety and efficacy of lisdexamfetamine dimesylate in the adult workplace environment was conducted. Clinical ...

      Known for Lisdexamfetamine Dimesylate | Life Adults | Reported Quality | Attention Deficit | Disorder Hyperactivity
      KOL-Index: 7485

      OBJECTIVE: To assess effects of OROS methylphenidate on cognitive and academic tasks in 9 to 12 year olds with attention-deficit/hyperactivity disorder (ADHD).

      METHODS: A double-blind, within-subject, crossover design was used to compare OROS methylphenidate with placebo in a laboratory classroom setting on several cognitive and academic tasks for 68 children who met randomization criteria.

      RESULTS: Performance on the following measures was significantly better when children received ...

      Known for Oros Methylphenidate | Cognitive Tasks | Hyperactivity Disorder | Attention Deficit | Adhd Symptoms
      KOL-Index: 7256

      The objective of this study was to evaluate the safety and efficacy of dexmethylphenidate extended-release (d-MPH-ER) 30 versus 20 mg in children with attention-deficit/hyperactivity disorder (ADHD) in a 12-hour laboratory classroom setting. In a randomized, double-blind, 3-period × 3-treatment, crossover study, children aged 6 to 12 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-diagnosed ADHD previously stabilized on MPH (40-60 mg/d) or D-MPH (20-30 ...

      Known for Hyperactivity Disorder | 30 Mph | Versus 20 | Attention Deficit | 165 Children
      KOL-Index: 3636

      Background and Objective: The primary objective of this study was to characterize the pharmacokinetic profile of pantoprazole delayed-release granules in infants and children aged 1 month to <6 years with gastro-oesophageal reflux disease (GORD). The studies described in this manuscript were conducted to fulfil the requirements of the paediatric written request for pantoprazole by the US FDA.Methods: Two randomized, open-label, multicentre studies were conducted in infants aged 1 month ...

      Known for Reflux Disease | Infants Children | Proton Pump | Gastro Oesophageal | 12 Months

      Key People For Lisdexamfetamine Dimesylate

      Top KOLs in the world
      #1
      JOSEPH Biederman
      bipolar disorder attention deficit adults adhd
      #2
      Suma Krishnan
      lisdexamfetamine dimesylate children adhd hyperactivity disorder
      #3
      Yuxin Zhang
      lisdexamfetamine dimesylate adderall xr plasma concentrations
      #4
      Ann Catherine Childress
      hyperactivity disorder lisdexamfetamine dimesylate aptensio xr
      #5
      Lenard A Adler
      adult adhd hyperactivity disorder lisdexamfetamine dimesylate
      #6
      Stephen V Faraone∗
      hyperactivity disorder attention deficit children adhd

      From the &amp;ast;Menninger Department of Psychiatry, Baylor College of Medicine,Houston; †Westex Clinical Investigations, Lubbock, TX; ‡US Medical, Novartis Pharmaceuticals Corporation, East Hanover, NJ; §Pediatric Trials Division, Clinical Study Ce

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.